Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

Purpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial t...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiujing Huang, Qi Zhang, Yu Xu, Xunda Ji, Ping Fei, Jie Peng, Yi-an Li, Peiquan Zhao
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2017/1741386
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849469033899884544
author Qiujing Huang
Qi Zhang
Yu Xu
Xunda Ji
Ping Fei
Jie Peng
Yi-an Li
Peiquan Zhao
author_facet Qiujing Huang
Qi Zhang
Yu Xu
Xunda Ji
Ping Fei
Jie Peng
Yi-an Li
Peiquan Zhao
author_sort Qiujing Huang
collection DOAJ
description Purpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial treatment. Patients were classified into the asymmetric outcome group and the symmetric outcome group. Results. Eighty-four patients (168 eyes) were included. There were 18 eyes of 9 patients (10.7%) in the asymmetric outcome group and 150 eyes of 75 patients (89.3%) in the symmetric outcome group. In the symmetric outcome group, 86 eyes (57.3%) had ROP regression, 60 eyes (40%) had reactivation requiring laser treatment, and 4 eyes (2.7%) progressed to retinal detachment requiring vitrectomy. In the asymmetric outcome group, one of the eyes of the 9 patients had ROP regression with/without reactivation after IVR, while the contralateral eyes had negative response, including remarkable posterior fibrosis, partial or total retinal detachment, and vitreous hemorrhage. There was statistically significant difference between the birth weight of the two groups. Conclusion. Contralateral eyes with ROP can take a different clinical course after ranibizumab treatment. High rate of reactivation after IVR is another concern that ophthalmologists should pay attention to.
format Article
id doaj-art-f7aa02c6f11c4637b9789377b55c7f9b
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-f7aa02c6f11c4637b9789377b55c7f9b2025-08-20T03:25:39ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/17413861741386Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab TreatmentQiujing Huang0Qi Zhang1Yu Xu2Xunda Ji3Ping Fei4Jie Peng5Yi-an Li6Peiquan Zhao7Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaPurpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial treatment. Patients were classified into the asymmetric outcome group and the symmetric outcome group. Results. Eighty-four patients (168 eyes) were included. There were 18 eyes of 9 patients (10.7%) in the asymmetric outcome group and 150 eyes of 75 patients (89.3%) in the symmetric outcome group. In the symmetric outcome group, 86 eyes (57.3%) had ROP regression, 60 eyes (40%) had reactivation requiring laser treatment, and 4 eyes (2.7%) progressed to retinal detachment requiring vitrectomy. In the asymmetric outcome group, one of the eyes of the 9 patients had ROP regression with/without reactivation after IVR, while the contralateral eyes had negative response, including remarkable posterior fibrosis, partial or total retinal detachment, and vitreous hemorrhage. There was statistically significant difference between the birth weight of the two groups. Conclusion. Contralateral eyes with ROP can take a different clinical course after ranibizumab treatment. High rate of reactivation after IVR is another concern that ophthalmologists should pay attention to.http://dx.doi.org/10.1155/2017/1741386
spellingShingle Qiujing Huang
Qi Zhang
Yu Xu
Xunda Ji
Ping Fei
Jie Peng
Yi-an Li
Peiquan Zhao
Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
Journal of Ophthalmology
title Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
title_full Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
title_fullStr Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
title_full_unstemmed Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
title_short Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
title_sort asymmetric outcomes of type 1 retinopathy of prematurity after bilateral intravitreal ranibizumab treatment
url http://dx.doi.org/10.1155/2017/1741386
work_keys_str_mv AT qiujinghuang asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT qizhang asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT yuxu asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT xundaji asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT pingfei asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT jiepeng asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT yianli asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment
AT peiquanzhao asymmetricoutcomesoftype1retinopathyofprematurityafterbilateralintravitrealranibizumabtreatment